Works by Ragupathi, Govind

Results: 21

Development of a minimal saponin vaccine adjuvant based on QS-21.

Published in:

Nature Chemistry, 2014, v. 6, n. 7, p. 635, doi. 10.1038/nchem.1963

By:

Fernández-Tejada, Alberto;
Chea, Eric K.;
George, Constantine;
Pillarsetty, NagaVaraKishore;
Gardner, Jeffrey R.;
Livingston, Philip O.;
Ragupathi, Govind;
Lewis, Jason S.;
Tan, Derek S.;
Gin, David Y.

Publication type:

Article

Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody.

Published in:

Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.222844

By:

Carrasquillo, Jorge A.;
Fine, Bernard M.;
Pandit-Taskar, Neeta;
Larson, Steven M.;
Fleming, Stephen E.;
Fox, Josef J.;
Cheal, Sarah M.;
O'Donoghue, Joseph A.;
Ruan, Shutian;
Ragupathi, Govind;
Lyashchenko, Serge K.;
Humm, John;
Scher, Howard I.;
Gönen, Mithat;
Williams, Simon P.;
Danila, Daniel C.;
Morris, Michael J.

Publication type:

Article

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Published in:

Journal of Nuclear Medicine, 2019, v. 60, n. 11, p. 1517, doi. 10.2967/jnumed.118.222844

By:

Carrasquillo, Jorge A.;
Fine, Bernard M.;
Pandit-Taskar, Neeta;
Larson, Steven M.;
Fleming, Stephen E.;
Fox, Josef J.;
Cheal, Sarah M.;
O'Donoghue, Joseph A.;
Ruan, Shutian;
Ragupathi, Govind;
Lyashchenko, Serge K.;
Humm, John L.;
Scher, Howard I.;
Gönen, Mithat;
Williams, Simon P.;
Danila, Daniel C.;
Morris, Michael J.

Publication type:

Article

Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology.

Published in:

Journal of Nuclear Medicine, 2013, v. 54, n. 11, p. 1876, doi. 10.2967/jnumed.113.119867

By:

Viola-Villegas, Nerissa Therese;
Rice, Samuel L.;
Carlin, Sean;
Xiaohong Wu;
Evans, Michael J.;
Sevak, Kuntal K.;
Drobjnak, Marija;
Ragupathi, Govind;
Sawada, Ritsuko;
Scholz, Wolfgang W.;
Livingston, Philip O.;
Lewis, Jason S.

Publication type:

Article

Molecular basis of antibody binding to mucin glycopeptides in lung cancer.

Published in:

International Journal of Oncology, 2016, v. 48, n. 2, p. 587, doi. 10.3892/ijo.2015.3302

By:

JIN QU;
HONGTAO YU;
FENGE LI;
CHUNLEI ZHANG;
TRAD, AHMAD;
CORY BROOKS;
BIN ZHANG;
TING GONG;
ZHI GUO;
YUNSEN LI;
RAGUPATHI, GOVIND;
YANYAN LOU;
PATRICK HWU;
WEI HUANG;
DAPENG ZHOU

Publication type:

Article

Synthesis of QS-21-Xylose: Establishment of the Immunopotentiating Activity of Synthetic QS-21 Adjuvant with a Melanoma Vaccine.

Published in:

Angewandte Chemie International Edition, 2008, v. 47, n. 34, p. 6395, doi. 10.1002/anie.200801885

By:

Deng, Kai;
Adams, Michelle M.;
Damani, Payal;
Livingston, Philip O.;
Ragupathi, Govind;
Gin, David Y.

Publication type:

Article

HLA-DR peptide occupancy can be regulated with a wide variety of small molecules.

Published in:

Human Vaccines & Immunotherapeutics, 2016, v. 12, n. 3, p. 593, doi. 10.1080/21645515.2015.1089370

By:

Blazekovic, Francesca;
Odukoya, Dana;
Butler, Shanitra N.;
Mauro, James A.;
Ramsamooj, Michael;
Puleo, Erika;
Szekeres, Karoly;
Dana, Dibyendu;
Kumar, Sanjai;
Ragupathi, Govind;
Blanck, George

Publication type:

Article

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

Published in:

Cancers, 2016, v. 8, n. 4, p. 46, doi. 10.3390/cancers8040046

By:

O'Cearbhaill, Roisin E.;
Ragupathi, Govind;
Jianglong Zhu;
Qian Wan;
Mironov, Svetlana;
Guangbin Yang;
Spassova, Maria K.;
Iasonos, Alexia;
Kravetz, Sara;
Ouerfelli, Ouathek;
Spriggs, David R.;
Danishefsky, Samuel J.;
Sabbatini, Paul J.

Publication type:

Article

Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 183, doi. 10.1007/s00262-022-03225-1

By:

Kahn, Ryan M.;
Ragupathi, Govind;
Zhou, Qin C.;
Iasonos, Alexia;
Kravetz, Sara;
Hensley, Martee L.;
Konner, Jason A.;
Makker, Vicky;
Tew, William P.;
Aghajanian, Carol;
Sabbatini, Paul J.;
O'Cearbhaill, Roisin E.

Publication type:

Article

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.

Published in:

Cancer Immunology, Immunotherapy, 2012, v. 61, n. 1, p. 9, doi. 10.1007/s00262-011-1083-6

By:

Krug, Lee;
Ragupathi, Govind;
Hood, Chandra;
George, Constantine;
Hong, Feng;
Shen, Ronglai;
Abrey, Lauren;
Jennings, Harold;
Kris, Mark;
Livingston, Philip

Publication type:

Article

Impact of minimal tumor burden on antibody response to vaccination.

Published in:

Cancer Immunology, Immunotherapy, 2011, v. 60, n. 5, p. 621, doi. 10.1007/s00262-011-0975-9

By:

Kim, Soo-Kie;
Wu, Xiaohong;
Ragupathi, Govind;
Gathuru, John;
Koide, Fusataka;
Cheung, Nai-Kong;
Panageas, Katherine;
Livingston, Philip

Publication type:

Article

Synthesis of sialyl Lewisa (sLea, CA19-9) and construction of an immunogenic sLea vaccine.

Published in:

Cancer Immunology, Immunotherapy, 2009, v. 58, n. 9, p. 1397, doi. 10.1007/s00262-008-0654-7

By:

Ragupathi, Govind;
Damani, Payal;
Srivastava, Geeta;
Srivastava, Om;
Sucheck, Steven J.;
Ichikawa, Yoshi;
Livingston, Philip O.

Publication type:

Article

A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”.

Published in:

Cancer Immunology, Immunotherapy, 2007, v. 56, n. 12, p. 1921, doi. 10.1007/s00262-007-0335-y

By:

Slovin, Susan F.;
Ragupathi, Govind;
Fernandez, Celina;
Diani, Meghan;
Jefferson, Matthew P.;
Wilton, Andrew;
Kelly, W. Kevin;
Morris, Michael;
Solit, David;
Clausen, Henrik;
Livingston, Philip;
Scher, Howard I.

Publication type:

Article

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Published in:

Cancer Immunology, Immunotherapy, 2005, v. 54, n. 7, p. 694, doi. 10.1007/s00262-004-0598-5

By:

Slovin, Susan;
Ragupathi, Govind;
Musselli, Cristina;
Fernandez, Celina;
Diani, Meghan;
Verbel, David;
Danishefsky, Samuel;
Livingston, Philip;
Scher, Howard

Publication type:

Article

Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.

Published in:

Cancer Immunology, Immunotherapy, 2005, v. 54, n. 5, p. 424, doi. 10.1007/s00262-004-0584-y

By:

Kagan, Ella;
Ragupathi, Govind;
Yi, San;
Reis, Celso;
Gildersleeve, Jeff;
Kahne, Daniel;
Clausen, Henrik;
Danishefsky, Samuel;
Livingston, Philip

Publication type:

Article

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.

Published in:

Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 608, doi. 10.1007/s00262-003-0399-2

By:

Ragupathi, Govind;
Koide, Fusataka;
Sathyan, Natarajan;
Kagan, Ella;
Spassova, Maria;
Bornmann, William;
Gregor, Polly;
Reis, Celso A.;
Clausen, Henrik;
Danishefsky, Samuel J.;
Livingston, Philip O.

Publication type:

Article

Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Published in:

Immunology, 2008, v. 123, n. 1, p. 145, doi. 10.1111/j.1365-2567.2007.02760.x

By:

Jun-Eui Park;
Wu, Dianna Y.;
Prendes, Maria;
Lu, Sharon X.;
Ragupathi, Govind;
Schrantz, Nicolas;
Chapman, Paul B.

Publication type:

Article

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.

Published in:

Cancers, 2021, v. 13, n. 24, p. 6265, doi. 10.3390/cancers13246265

By:

Cardenas, Fiorella Iglesias;
Mauguen, Audrey;
Cheung, Irene Y.;
Kramer, Kim;
Kushner, Brian H.;
Ragupathi, Govind;
Cheung, Nai-Kong V.;
Modak, Shakeel

Publication type:

Article

Correction: Mitochondrial Ceramide-Rich Macrodomains Functionalize Bax upon Irradiation.

Published in:

PLoS ONE, 2015, v. 10, n. 12, p. 1, doi. 10.1371/journal.pone.0146210

By:

Lee, Hyunmi;
Rotolo, Jimmy A.;
Mesicek, Judith;
Penate-Medina, Tuula;
Rimner, Andreas;
Liao, Wen-Chieh;
Yin, Xianglei;
Ragupathi, Govind;
Ehleiter, Desiree;
Gulbins, Erich;
Zhai, Dayong;
Reed, John C.;
Haimovitz-Friedman, Adriana;
Fuks, Zvi;
Kolesnick, Richard

Publication type:

Article

Mitochondrial Ceramide-Rich Macrodomains Functionalize Bax upon Irradiation.

Published in:

PLoS ONE, 2011, v. 6, n. 6, p. 1, doi. 10.1371/journal.pone.0019783

By:

Hyunmi Lee;
Rotolo, Jimmy A.;
Mesicek, Judith;
Penate-Medina, Tuula;
Rimner, Andreas;
Liao, Wen-Chieh;
Xianglei Yin;
Ragupathi, Govind;
Ehleiter, Desiree;
Gulbins, Erich;
Dayong Zhai;
Reed, John C.;
Haimovitz-Friedman, Adriana;
Zvi Fuks;
Kolesnick, Richard

Publication type:

Article

Carbohydrate vaccines as immunotherapy for cancer.

Published in:

Immunology & Cell Biology, 2005, v. 83, n. 4, p. 418, doi. 10.1111/j.1440-1711.2005.01350.x

By:

Slovin, Susan F;
Keding, Stacy J;
Ragupathi, Govind

Publication type:

Article

Works by Ragupathi, Govind

Development of a minimal saponin vaccine adjuvant based on QS-21.

Imaging metastatic castration-resistant prostate cancer patients with <sup>89</sup>Zr-DFO-MSTP2109A anti-STEAP1 antibody.

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology.

Molecular basis of antibody binding to mucin glycopeptides in lung cancer.

Synthesis of QS-21-Xylose: Establishment of the Immunopotentiating Activity of Synthetic QS-21 Adjuvant with a Melanoma Vaccine.

HLA-DR peptide occupancy can be regulated with a wide variety of small molecules.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.

Impact of minimal tumor burden on antibody response to vaccination.

Synthesis of sialyl Lewis<sup>a</sup> (sLe<sup>a</sup>, CA19-9) and construction of an immunogenic sLe<sup>a</sup> vaccine.

A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.

Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.

Correction: Mitochondrial Ceramide-Rich Macrodomains Functionalize Bax upon Irradiation.

Mitochondrial Ceramide-Rich Macrodomains Functionalize Bax upon Irradiation.

Carbohydrate vaccines as immunotherapy for cancer.